These abstracts from the American Society of Hematology’s 2016 annual meeting caught our attention for their potential impact on clinical practice and research in the field.
Pacritinib Outperforms Best Available Therapy for Myelofibrosis
The oral kinase inhibitor pacritinib (PAC) yielded greater spleen volume reduction than best available therapy — including ruxolitinib — for myelofibrosis patients. If PAC passes the safety test, the impact could be huge.
Vadastuximab for AML: Investigator Predicts Changes to Standard Therapy in Near Future
AML studies report effectiveness of vadastuximab, an anti-CD33 drug conjugate, in various regimens including combined with azacitidine and as part of maintenance regimens. Investigators predict changes to standard treatment of AML in the near future.
Study: Eltrombopag May Help Hasten Platelet Recovery in Acute Myeloid Leukemia
Cleveland Clinic researchers are first to test eltrombopag during 7+3 induction chemotherapy in AML. Interim data suggest eltrombopag can accelerate platelet recovery and potentially reduce the need for platelet transfusions.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Study Identifies Predictors of Bleeding in Hospitalized Cancer Patients
Cleveland Clinic researchers identified risk factors predictive of bleeding events among hospitalized cancer patients. Findings may help optimize appropriateness of thromboprophylaxis.
Study Examines Pain and Quality of Life in Hemophilia Patients
A newly validated set of patient-reported outcomes in hemophilia correlate well with social and demographic data. Findings may help individualize care and optimize patient well-being.
Pomalidomide Tames Refractory Bleeding in Rare Hemorrhagic Disorder
Cleveland Clinic researchers are first to test pomalidomide for refractory bleeding in hereditary hemorrhagic telangiectasia. Interim data signals reduced bleeding and reduced need for transfusions.
Novel Drug Regimen Shows Promise for Sickle Cell Disease
Tetrahydrouridine renders decitabine orally bioavailable at nontoxic doses in first-in-human trial, safely increasing fetal hemoglobin (HbF) up to twofold in patients with sickle cell disease.
ASH 2016 – Saturday, December 3
Please join our staff as we participate or present in the following oral and poster presentations at the 2016 ASH Annual Meeting
ASH 2016 – Sunday, December 4
Please join our staff as we participate or present in the following oral and poster presentations at the 2016 ASH Annual Meeting